Recent advances in the molecular understanding of glioblastoma by Bleeker, Fonnet E. et al.
TOPIC REVIEW
Recent advances in the molecular understanding of glioblastoma
Fonnet E. Bleeker • Remco J. Molenaar •
Sieger Leenstra
Received: 29 May 2011/Accepted: 27 December 2011/Published online: 20 January 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Glioblastoma is the most common and most
aggressive primary brain tumor. Despite maximum treat-
ment, patients only have a median survival time of
15 months, because of the tumor’s resistance to current
therapeutic approaches. Thus far, methylation of the
O
6-methylguanine-DNA methyltransferase (MGMT) pro-
moter has been the only conﬁrmed molecular predictive
factor in glioblastoma. Novel ‘‘genome-wide’’ techniques
have identiﬁed additional important molecular alterations as
mutations in isocitrate dehydrogenase 1 (IDH1) and its
prognosticimportance.Thisreviewsummarizesﬁndingsand
techniques of genetic, epigenetic, transcriptional, and pro-
teomic studies of glioblastoma. It provides the clinician with
an up-to-date overview of current identiﬁed molecular altera-
tions that should ultimately lead to new therapeutic targets
andmoreindividualizedtreatmentapproachesinglioblastoma.
Keywords Glioblastoma  Molecular  (Epi)genetic 
Transcriptional  Proteomic
Introduction
Glioblastoma, or astrocytoma WHO grade IV, is the most
fatal primary brain cancer found in humans. Most glio-
blastomas manifest rapidly de novo, without recognizable
precursor lesions. These primary glioblastomas present in
elderly patients with a brief clinical history and are char-
acterized by rapid progression and short survival time.
A small group of young patients has a history of epilepsy
caused by low-grade gliomas which, within years, progress
to secondary glioblastoma. A secondary glioblastoma
occurs in *5% of glioblastoma patients, and can only be
diagnosed with clinical (neuroimaging) or histological
evidence of its evolution from a less malignant glioma [1].
The standard treatment for newly diagnosed glioblas-
toma patients is gross total removal, if possible, followed
by the combination of the alkylating cytostatic drug tem-
ozolomide (TMZ) and RT [2, 3]. Median overall survival is
15 months only [3], although for a rare group of long-term
survivors (2–5%) survival time exceeds 3 years [4, 5].
Differences between patients and their performance status
lead to variation in survival, which can be calculated for
individual patients by means of nomograms [6]. A better
prognosis is associated with younger age, better perfor-
mance status, and more extensive surgical resection
followed by TMZ and RT [6]. In contrast with many other
malignancies, however, there have only been small
improvements in the glioblastoma patient’s prognosis over
recent decades. Nevertheless, understanding of the molec-
ular alterations in signaling pathways and the consequent
pathology in glioblastoma has greatly increased in recent
years and is beginning to match that of other types of
cancer.
This review provides an overview of the molecular
alterations in glioblastoma (Fig. 1)[ 7–9]. They are
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underlie transformation to the neoplastic phenotype, start-
ing from (epi)genetic, via transcriptional, to proteomic
studies of glioblastoma. The important molecular altera-
tions, which have been identiﬁed by novel ‘‘genome-wide’’
techniques, are discussed in relation to gliomagenesis and
glioma progression and in relation to clinical subgroups
and prognosis. Finally, we discuss the application of these
new insights in the light of future prospects for experi-
mental and clinical practice in neuro-oncology.
Genomic and genetic variants
Genomic instability
Genomic instability is one of the enabling characteristics of
cancer [10]. It can be broadly differentiated into chromo-
some instability (CIN) and microsatellite instability (MIN
or MSI). Cytogenetic studies of glioblastoma have shown
that most tumors are near-diploid, and that numerical and
structural chromosomal abnormalities are common [11].
MSI is rarely observed for non-inherited newly diagnosed
glioblastomas, because of inactivation of mismatch repair
(MMR) genes [12]. However, in recurrent glioblastomas
after TMZ treatment, inactivating mutations have been
observed in MSH6, one of the MMR genes. MSH6 muta-
tions have not been associated with detectable MSI as
manifested by changes in the length of microsatellite
sequences, but with a hypermutator phenotype [7, 9, 13].
As genetic alterations and genomic instability are closely
linked with each other, it is an interesting ﬁnding that in
glioblastoma, tumors from short-term survivors have more
genetic alterations than long-term survivors’ tumors [5].
Chromosomal alterations
Techniques
Evolving techniques have identiﬁed increasingly more
detailed chromosomal alterations.
Karyograms [11], ﬂuorescent in situ hybridization
(FISH) analyses [14], and comparative genomic hybrid-
ization (CGH) [15, 16] have preceded whole-genome
single nucleotide polymorphism (SNP)-based arrays. Whereas
karyograms are able to reveal only gross chromosomal
changes, SNP-based arrays have the ability to detect copy
number alterations (CNAs), varying from complete
Fig. 1 Simpliﬁed
representation and integration of
three commonly altered
pathways involved in
glioblastoma. Upper panel, the
growth factor receptor/PI3K/
AKT pathway. The lower
panels depict the RB pathway
(left) and the P53 pathway
(right). Proteins that potentially
act as tumor suppressors are
indicated in green whereas
oncoproteins are indicated in
red. The growth factors binding
to the receptors have been
depicted in yellow
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123chromosomal changes to small intragenic deletions. In
addition, it is possible to distinguish signals from individ-
ual alleles and therefore reveal copy-number-neutral
(CNN) loss of heterozygosity (LOH). Here, a chromosome
segment is lost, whereas the corresponding homologous
region is duplicated, resulting in a neutral copy number.
For example, 17p, which contains TP53, is a signiﬁcant
region of CNN LOH in glioblastoma [7, 8].
Among chromosomal alterations, ampliﬁcations and
deletions can be distinguished. Of these, the most common
in glioblastoma will be discussed here. Reports of inci-
dental translocations are rare in glioblastoma [17]; conse-
quently, translocations may not be important in the
development of glioblastoma and will not be discussed
further.
Ampliﬁcations
Ampliﬁcation of the epidermal growth factor receptor
(EGFR) gene is a characteristic ﬁnding in primary glio-
blastoma (Table 1)[ 5, 8, 16, 18]. Focal (restricted to a few
Mb) and broader (from several Mbs to whole chromo-
somes) CNAs that include the EGFR gene may have dif-
ferent molecular consequences [16]. Focal ampliﬁcation of
EGFR correlates with EGFR overexpression or mutations
and deletions in the EGFR gene, and subsequent activation
of the PI3K/AKT pathway [16, 19]. Upregulated PI3K/
AKT signaling has been associated with a poor prognosis
[20, 21]. Ampliﬁcation of the complete chromosome 7,
containing EGFR, MET [7], and its ligand HGF, has been
found to correlate with activation of the MET axis [16].
Furthermore, EGFR ampliﬁcation is reported to appear as
double minutes (small fragments of extrachromosomal
DNA), and extra copies of EGFR have also been found
inserted into different loci on chromosome 7 [22].
Remarkably, gain of chromosome 7 and ampliﬁcation of
EGFR have been found more frequently in short-term
survivors [4, 5], however EGFR alterations are not of
prognostic importance in glioblastoma [4, 18, 23].
Ampliﬁcation of 12q13-15, where the oncogenes CDK4
and MDM2 are located, results in the disruption of both the
RB and P53 pathways [7, 8, 16, 24]. The genes encoding
the receptor tyrosine kinases KIT, KDR, and PDGFRA,
adjacently located on chromosome 4q12, are frequently
found to be (co)ampliﬁed [25]. Other ampliﬁed regions
containing oncogenes, for example AKT3 [7, 26] and
CCND2 [7, 16], are listed in Table 1.
Deletions
LOH of chromosome 10q is the most common genomic
alteration found in both primary and secondary glioblas-
tomas [18, 24] (Table 1) and is associated with poor
survival [5, 18]. Different regions are frequently lost at
chromosome 10, including the regions containing PTEN,
MGMT [1, 18], and ANXA7, an EGFR inhibitor [27].
Another frequently deleted inhibitor of EGFR signaling is
NFKBIA, which is located on chromosome 14; this deletion
is associated with poor survival [28]. Furthermore, loss of
chromosome 9p, which contains a variety of tumor-sup-
pressor genes, including CDKN2A, CDKN2B, and PTPRD,
is frequently seen [8, 18, 29], especially in short-term
survivors [4, 5]. CDKN2A and CDKN2B encode three
important cell cycle proteins, p14
ARF and p16
INK4A, and
p15
INK4B [5, 8, 15, 16, 18], which are involved in the RB
and P53 pathways. Deletion of CDKN2A and CDKN2B is
often accompanied by deletion of CDKN2C on chromo-
some 1p32, which encodes another cell cycle protein
p18
INK4C [15]. LOH of chromosome 1p is found in both
primary and secondary glioblastomas [30]. Longstanding
speculation about the potentially located tumor suppressor
gene at 1p has recently been advanced by identiﬁcation
of the suggested candidate genes CIC and FUPB1 [31].
Co-deletion of 1p and 19q is frequently seen in oligoden-
drogliomas and is, in those, associated with prolonged
survival [4] and translocations [32]. Although this
co-deletion has been observed in glioblastomas, no similar
association has been identiﬁed. Isolated LOH 19q, how-
ever, is frequently observed in secondary glioblastoma
[5, 30] and may be a marker of longer survival [5].
Somatic mutations
Techniques
In addition to ampliﬁcations and deletions, genes impli-
cated in glioblastoma can be affected by somatic muta-
tions. Mutation analysis has identiﬁed mutations activating
oncogenes and others inactivating tumor-suppressor genes
in glioblastoma [7, 9, 33]. The recommended method used
to be direct or Sanger sequencing after ampliﬁcation of the
suspected locus by means of polymerase chain reaction
(PCR). Nowadays, improved sequencing techniques are
being developed and rapidly applied to facilitate genome-
wide mutation analysis [34].
Mutations frequently found in glioblastoma
Mutations in ‘‘common’’ cancer genes, for example TP53
and PTEN, are very frequent in glioblastomas, but are not
of prognostic importance (Table 2)[ 4, 7, 9, 18, 23, 33].
Furthermore, glioblastoma-speciﬁc mutations are seen; the
EGFRvIII mutant lacks 267 amino acids in the extracellular
part, resulting in a constitutively activated receptor that no
longer requires its ligand EGF to signal downstream [35].
EGFR point mutations have also been identiﬁed in
J Neurooncol (2012) 108:11–27 13
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123glioblastoma, in the extracellular domain, whereas they are
predominantly found in the kinase domain in other tumor
types, for example lung cancer [36]. Two extensive
mutational studies have provided an overview of the most
common mutations affecting glioblastoma (Table 2)[ 7, 9].
Although mutations in ‘‘common’’ cancer genes, for
example BRAF and the RAS genes, have rarely been
observed in gliomas (\5%) [37], inactivating mutations
and deletions have been identiﬁed in their inhibitory tumor
suppressor gene NF1 [7]. Mutations in PIK3CA and
PIK3R1, coding, respectively, for the PI3K catalytic sub-
unit p110a and regulatory subunit P85a, have been
described [7, 9].
The incidence of mutation in glioblastoma is lower than
in other solid tumors [38], with the exception of the
hypermutator phenotype [13], which, as described above, is
found in recurrent glioblastomas after treatment with
alkylating agents. This may be caused by MGMT methyl-
ation or mutational inactivation of DNA-repair enzymes,
for example MSH6 [7, 9, 13].
IDH1 mutations
An interesting gene found to contain mutations in glio-
blastoma is IDH1, which encodes isocitrate dehydrogenase
1 and is involved in energy metabolism [9]. IDH1 muta-
tions have been predominantly identiﬁed in secondary
glioblastomas and low-grade gliomas, with mutations in
more than 70% of cases [9, 39–43]; they are found only
sporadically in primary glioblastomas [9, 41–44]. Because
patients with IDH1 mutated primary glioblastomas are
generally younger and have longer median survival and
wild-type EGFR, which are characteristics of secondary
glioblastomas, it is hypothesized that these are in fact
secondary glioblastomas for which no histological
evidence of evolution from a less malignant glioma is
found. Therefore, IDH1 could be used to differentiate
primary from secondary glioblastomas [41]. In different
glioblastoma studies IDH1 mutations have been found to
be an independent positive prognostic marker [9, 40, 44,
45]. IDH1 mutations have been shown to inactivate the
enzyme with subsequent HIF-1a induction [42, 44, 46]. In
addition, the mutations result in gain of function to catalyze
a-ketoglutarate (a-KG) to 2-hydroxyglutarate (2-HG) [47].
Furthermore, 2-HG inhibits histone demethylases and TET
5-methylcytosine hydroxylases. These a-KG dependent
dioxygenases are thought to be involved in epigenetic
control. This suggests that mutations in IDH1 change the
expression of a potentially large number of genes [48].
Given that mutations in IDH1 are an early event in gli-
omagenesis (Fig. 2)[ 49], this may implicate widespread
alteration of epigenetic control as the key mechanism in
gliomagenesis in IDH1 mutated tumors. Furthermore,
it might explain the extensive and fundamental differences
between mutated and wildtype IDH1 glioblastoma.
Polymorphisms
Family members of glioma patients are more susceptible to
glioma and other cancer types [50], suggesting a genetic
origin. The most common type of genetic variation is
formed by single nucleotide polymorphisms (SNPs).
A SNP is a single base-pair alteration at a speciﬁc locus.
They can be identiﬁed by PCR for single loci or use of
Table 2 Genes frequently found to be mutated in glioblastoma
Gene symbol Gene name Function of encoded protein Point mutation (%) Refs.
EGFR Epidermal growth factor receptor Regulator of cell signaling, involved
in cell proliferation and survival
14–15 [7, 9, 36]
ERBB2 V-erb-b2 erythroblastic leukemia viral
oncogene homolog 2
Regulator of cell signaling, involved
in cell proliferation and survival
0–7 [7, 9]
IDH1 Isocitrate dehydrogenase 1 (NADP?) NADPH production 12–20 [9, 39–42, 44]
NF1 Neuroﬁbromin 1 Regulator of cell signaling, involved
in cell proliferation and survival
15–17 [7, 9]
PIK3CA Phosphoinositide-3-kinase, catalytic,
alpha polypeptide
Regulator of cell signaling, involved
in cell proliferation and survival
7–10 [7, 9]
PIK3R1 Phosphoinositide-3-kinase, regulatory
subunit 1 (alpha)
Regulator of cell signaling, involved
in cell proliferation and survival
7–8 [7, 9]
PTEN Phosphatase and tensin homolog Regulator of cell signaling, involved
in cell proliferation and survival
24–37 [7, 9, 18]
PTPRD Protein tyrosine phosphatase,
receptor type, D
Regulator of cell signaling, involved
in cell proliferation and survival
0–6 [9]
RB1 Retinoblastoma 1 Regulator of cell cycle 8–13 [7, 9]
TP53 Tumor protein p53 Apoptosis 31–38 [7, 9, 18]
J Neurooncol (2012) 108:11–27 15
123SNP-based arrays for whole genome alterations. SNPs have
been linked to susceptibility to glioblastomas. In particular,
allergies and asthma’s inverse association with
glioblastoma have been observed in different studies and
have been linked with polymorphisms in HLA and inter-
leukins. This may suggest that immune factors play a role
Fig. 2 Genetic pathways
toward primary and secondary
glioblastoma
16 J Neurooncol (2012) 108:11–27
123in gliomagenesis [51]. SNP309 in MDM2 has been asso-
ciated with an increased risk of various types of cancer, but
has not been associated as a risk or prognostic factor in
respect of glioblastoma in large studies [52]. SNPs in
CDKN2B, TERT, and RTEL1 have been described in
independent studies as susceptibility loci for high-grade
glioma [53, 54]. In a follow-up study, SNPs in DNA
double-strand break repair enzymes, for example RTEL1,
have been found to correlate with glioblastoma survival
[55]. Various other SNPs have been correlated with glio-
blastoma survival and age of onset [55], however, these
studies’ ﬁndings have not yet been conﬁrmed.
Gene expression proﬁling
Techniques and results
Overexpression or underexpression of genes in glioblas-
toma compared with that in a normal brain or in low-grade
gliomas may be an indication of genes that are involved in
gliomagenesis (Table 3). Most of the 20,000–25,000 genes
encoded by the human genome are known [56], and these
have been applied to chips used for micro-arrays. Differ-
ences in expression of ‘‘unknown’’ genes can be studied by
serial analysis of gene expression (SAGE), by use of small
expression tags [57]. Large-scale expression studies are
usually validated by reverse transcription (RT)-PCR for
individual genes.
A high level of expression of insulin-like growth factor
binding proteins, for example IGFBP-2/3 [58], angioge-
nesic factors, for example vascular endothelial growth
factor A (VEGFA) [59], and mesenchymal markers, for
example YKL-40/CHI3L1, are frequently seen in glio-
blastoma (Table 3) and have been associated with poor
prognosis [60–62]. In contrast, NOTCH signaling genes,
for example DLL3, are indicative of better survival [63].
Furthermore, WEE1, a kinase that regulates the G2
checkpoint in glioblastoma cells, is commonly overex-
pressed in glioblastoma and higher expression has been
shown to correlate with worse patient survival [64].
Gene expression proﬁling studies outperform histology
for grading and prognosis
Low-grade astrocytomas have rather speciﬁc and consistent
expression proﬁles, whereas for primary glioblastomas
there is much larger variation between tumors. Further-
more, secondary glioblastomas have distinct expression
proﬁles and features of the other two types [65]. Expression
proﬁling of different types and grades of glioma has been
found to outperform histopathologic grading for prognosis
[20, 66–68]. To improve classiﬁcation of patients with
glioblastoma, a gene dosage expression incorporated model
based on seven genes (POLD2, CYCS, MYC, AKR1C3,
YME1L1, ANXA7, and PDCD4) has been generated. This
model can be used to categorize patients in risk groups with
different prognosis; a high-risk group in which C5o f7
genes are altered, a moderate-risk (3–4 genes), or a
low-risk group (B2 genes). In this study, MGMT methyl-
ation and IDH1 mutational status were not incorporated
[69]. A newer predictive model based on expression of four
genes (CHAF1B, PDLIM4, EDNRB, and HJURP) has been
generated, and is independent of MGMT methylation and
Table 3 Genes frequently found to be overexpressed in glioblastoma compared with either normal brain tissue or low-grade gliomas
Gene symbol Gene name Function of encoded protein Refs.
CD44 CD44 molecule Cell-cell interactions, cell adhesion and
migration
[20, 62]
DLL3 Delta-like 3 Notch signaling [20, 62]
EGFR Epidermal growth factor receptor Regulator of cell signaling, involved
in cell proliferation and survival
[62]
FABP7 Fatty acid binding protein 7 Fatty acid uptake, transport, and
metabolism
[62]
IGFBP2 Insulin-like growth factor binding protein 2 Regulation of cell growth [58–60, 62]
IGFBP3 Insulin-like growth factor binding protein 3 Regulation of cell growth [58]
MMP9 Matrix metallopeptidase 9 Extracellular matrix [62]
SPARC Secreted protein, acidic, cysteine-rich
(osteonectin)
Extracellular matrix [62]
TNC Tenascin C Cell adhesion [60, 62]
VEGFA Vascular endothelial growth factor A Angiogenesis, vasculogenesis, and
endothelial cell growth
[20, 59, 60, 62]
CHI3L1 Chitinase 3-like 1(YKL-40) Extracellular matrix [20, 60, 62]
VIM Vimentin Cytoskeletal element [20]
J Neurooncol (2012) 108:11–27 17
123IDH1 mutational status. Here, high expression of EDNRB
correlates with longer survival whereas the other genes are
correlated with higher risk of death. On the basis of the
expression of these 4 genes, low-risk and high-risk groups
were formed. Interestingly, survival was similar for
patients in the low-risk group with wildtype IDH1 and
patients in the high-risk group with mutated IDH1 [70].
Expression classiﬁcation and prognosis according
to TCGA studies
Studies by The Cancer Genome Atlas (TCGA) have
incorporated genomic alterations within expression analy-
ses. Distinct molecular subclasses in high-grade glioma
have been identiﬁed, delineating a pattern of disease pro-
gression that resembles stages in neurogenesis, and have
been used to classify glioblastomas into proneural, neural,
classic, and mesenchymal subtypes [20, 63, 71]. Proneural
glioblastomas are characterized by IDH1 mutations, and
TP53 and PDGFRA alterations, and correlate with a better
prognosis and younger age. Classic glioblastomas are dif-
ferentiated on the basis of high-level ampliﬁcation of
EGFR, monosomy of chromosome 10, and deletion of
CDKN2A. Neural glioblastomas are typiﬁed by expression
of neuron markers, and resemble normal brain most. Mes-
enchymal glioblastomas are known for NF1 deletion or
mutation and expression of YKL-40/CHI3L1 and MET [20,
71]. Different subtypes of glioblastoma have been shown to
behave differently in response to treatment; Classic and
mesenchymal subtypes have a survival advantage after
TMZ and RT, whereas the proneural subtype of glioblas-
tomas, with relative good prognostic, does not [71]. Strat-
iﬁed clinical trials in which patient inclusion is based on the
genetic alterations that have been identiﬁed in their tumor
samples are necessary to further increase our understanding
of the clinical possibilities of these subgroups.
Epigenetics
Epigenetic silencing mechanisms
Epigenetic silencing of tumor suppressor genes is a com-
mon phenomenon of genomic instability in cancer [10].
Epigenetics are inherited characteristics of gene expres-
sion, not related to nucleotide sequences. Examples are
promoter hypermethylation, histone deacetylation, histone
methylation, other histone modiﬁcations which can alter
chromatin structure (in)directly, and RNA-silencing
mechanisms such as RNA interference and microRNA
(miRNA or miR) regulation of gene expression [72]. In
contrast with the global DNA hypomethylation found in
glioblastoma and other tumors [73], tumor suppressor
genes are commonly found to be hypermethylated and,
hence, silenced [72]. DNA methylation, histone deacety-
lation, and miRs are best studied in glioblastoma and are
discussed next.
Methylation and histone deacetylation
In glioblastoma, similar to other cancers, global DNA hy-
pomethylation is often seen with hypermethylation of CpG
islands in promoter regions. Tumor-suppressor genes fre-
quently found to be silenced by hypermethylation in glio-
blastoma include CDKN2A, CDKN2B, RB1, PTEN, and
TP53. (reviewed elsewhere [74, 75]). Differences in various
genes’ promoter methylation have been found between
primary and secondary glioblastomas (Table 4)[ 76–78],
longandshort-termglioblastomasurvivors[75,79],primary
and recurrent tumors, and time to tumor progression [80].
MGMT methylation
Particularly important in glioblastoma is the methylation
status of MGMT, which is a predictive factor for therapy
response and hence survival of glioblastoma patients trea-
ted with TMZ and RT [2, 23, 81]. MGMT methylation has
been observed in 40–57% of glioblastomas; however,
speciﬁc subgroups have a higher frequency. MGMT
methylation has been found to be more frequent in sec-
ondary glioblastomas [82], in females [83], and in long-
term survivors (LTS) [4], whereas it is rare (5%) in
recurrent glioblastomas [84]. Conﬂicting results have been
reported regarding the methylation status of MGMT as a
positive prognostic marker [74, 75, 83]. TMZ and other
alkylating agents modify the O
6-position in guanines
thereby forming critical DNA lesions that progress to lethal
DNA cross-links which prohibit cell replication. The DNA
repair enzyme MGMT is able to remove alkyl groups, thus
introducing resistance to TMZ treatment. However, when
the promoter of MGMT is methylated, MGMT is not tran-
scribed and therefore cannot repair DNA damage caused
by TMZ, making TMZ more efﬁcient. The best means of
assessment of the MGMT methylation status has been
debated; the most widely recommended method is meth-
ylation-speciﬁc PCR (MSP) [85]. Recently, the methyla-
tion status of the FNDC3B, TBX3, DGKI, and FSD1
promoters was identiﬁed to be important in patients with
MGMT-methylated tumors who did not respond to TMZ
and RT treatment [79]. MGMT methylation is also asso-
ciated with pseudo-progression after concomitant radio-
chemotherapy for newly diagnosed glioblastoma patients
[86]. Furthermore, the pattern of recurrence, including time
to recurrence and location of the recurrent tumor, seems to
be correlated with the MGMT methylation status of the
primary tumor [87].
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123Hypermethylation phenotype
A subset of glioblastoma tumors has been found to contain
a hypermethylation phenotype at a large number of CpG
islands; this has been named the glioma-CpG island
methylator phenotype (G-CIMP) by the TCGA. These
G-CIMP tumors cluster into the aforementioned proneural
subgroup, are strongly associated with IDH1 mutations,
and generally affect younger patients with improved
prognosis [88]. Furthermore, inhibition of histone
demethylases and TET 5-methylcytosine hydroxylases by
mutated IDH1 potentially implies the methylation of an
even greater number of genes in this subgroup [48].
MicroRNAs
miRs are short non-coding RNAs, consisting of approxi-
mately 22 nucleotides, which regulate gene expression.
miRs usually inhibit target genes’ expression, either by
inhibiting translation or by triggering the cleavage of the
target mRNA. Over 700 miRs have been described in
humans [89]. By use of the same methods previously
described for gene expression, differences in miR expres-
sion have been examined. Compared with normal brain
tissue a variety of differentially expressed miRs have been
found (Table 5)[ 90–101].
OncomiRs, tumor suppressor miRs, and therapeutic
implications
Frequently up-regulated miRs are called oncomiRs. Of
these, miR-26a is found to target PTEN in glioblastomas
[102]. Furthermore, miR-26 cooperates with oncogenes
CDK4 and CENTG1, forming an oncomiR/oncogene
cluster, targeting the RB, PI3K/AKT, and JNK pathways
and increasing aggressiveness in glioblastoma [95]. miR-
221 and miR-222 are thought to target cell cyclin-depen-
dent kinase inhibitors p27 and p57 by targeting the pro-
apoptotic PUMA [103]. In contrast with these oncomiRs,
frequently down-regulated miRs in glioblastoma are con-
sidered tumor-suppressor miRs. Of these, miR-7 indepen-
dently inhibits both the EGFR and AKT pathways [98].
miR-34a suppresses glioblastoma growth by targeting
c-Met and Notch [99]. miR-124 and miR-137 target CDK6,
which is important in the G1/S-phase transition [97]. miR-
128 targets BMI1, which has been shown to promote stem
cell renewal [94]. Downregulation of miR-181 is found in
responders to temozolomide [100]. The delivery of un-
derexpressed tumor-suppressor miRs may be an appealing
approach for therapy. In contrast, overexpressed oncogenic
miRNas may be targeted by antagomirs, because overex-
pression of the oncomiRs miR-26a, miR-196, and miR-451
has been correlated with poorer survival [93]. A recent
review has provided an up-to-date overview on miRs and
their inhibitors for glioblastoma treatment and readers
should refer to this for more information [104].
Proteomics
Proteomic studies involve research on the ﬁnal structure,
function, and activity of proteins. Therefore, post-transla-
tional modiﬁcations on the transcript are included in the
results. Thus far, only a limited number of proteomic
studies have been performed on glioblastomas and there
are still conceptual and technical limitations to overcome
[105]. In general, samples are run on 2D gels, which show
protein patterns on the basis of size and charge. Proteins
identiﬁed in tumor samples but not in normal tissue sam-
ples are subsequently analyzed by mass spectrometry with
matrix-assisted laser desorption/ionization (MALDI) [106].
Thus far, glioma subtypes have been distinguished on the
basis of different protein patterns as primary and secondary
glioblastomas [107, 108]. Furthermore, on the basis of
proteome analysis, survival has been predicted in respect of
glioma subtypes [107]. Additionally, proteins’ phosphory-
lation status is a tool with which to identify activated
proteins. Consequently, activated receptor tyrosine kinases
[109, 110] and the downstream signaling pathways of
EGFRvIII have been identiﬁed in glioblastomas [111].
Other molecular aspects of glioblastomas
Molecular differences between primary and secondary
glioblastomas
Primary and secondary glioblastoma subtypes are histopa-
thologically indistinguishable, but differences can be dem-
onstrated by molecular markers at the epigenetic [77],
genetic [1, 18, 24], expression [65], and proteomic [108]
levels (Fig. 2; Table 4). Primary glioblastomas have a
greater prevalence of EGFR alterations, MDM2 duplica-
tions, PTEN mutations, and homozygous deletions of
CDKN2A[1,18].METampliﬁcation[24],overexpressionof
PDGFRA, and mutations in IDH1 and TP53 are more pre-
valent in secondary glioblastomas [1, 9, 18, 33, 39, 41, 43].
The sequential order of molecular alterations
Molecular alterations causing glioblastoma are thought to
occur in a sequential order, implicating different stages of
gliomagenesis (Fig. 2). For example, IDH1-inactivating
mutations seem to be an early event in gliomagenesis [43].
In contrast, PTEN mutations and LOH 10q are thought to
be important in glioma progression, but not initiation [18].
20 J Neurooncol (2012) 108:11–27
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Taking into consideration all the molecular alterations
found in glioblastomas, it is clear that the picture of the
changes in gliomablastoma becomes more complex as the
techniques that enable us to investigate molecular mecha-
nisms develop. The good news is, however, that many of the
alterations identiﬁed in glioblastoma cluster in three path-
ways, the P53 (64–87%), RB (68–78%), and the PI3K/AKT
(50%), downstream of the receptor tyrosine kinases (altered
88% in total; Fig. 1). Most alterations occur in a mutually
exclusive fashion: alterations within one tumor affect only a
single gene in a pathway, suggesting that different genes in
a pathway are functionally equivalent [7–9, 71].
Quality of models
Functional validation of the identiﬁed molecular changes is
essential before they can be assessed as targets for therapy.
Taking this into account, it becomes clear that good models
are needed for high-throughput testing of rationally
designed combinations of drugs with speciﬁc targets.
Several experiments have shown that established glio-
blastoma cell lines resemble those of the original glio-
blastomas very poorly when compared at the level of DNA
alterations or gene expression proﬁles [71]. Tumor neuro-
spheres cultured in stem cell medium, organotypic spheroid
cultures, or low-passage monolayer cultures, resemble the
original tumors better and may be better models for study
of glioblastomas in vitro [112, 113].
Therapeutic options, multimodal therapy, and delivery
options
For optimum application of the insights presented in this
paper, stratiﬁed clinical trials are necessary to investigate
the best treatment options for each common (group of)
genetic alteration(s) in glioblastomas. Ultimately, this
could lead to more individualized therapies. Rational drug
design and rationally designed clinical trials to test these
drugs are needed, because an almost inﬁnite number of
compounds is currently available, and these can be tested
in limitless numbers of combinations. With genomics
approaches, discoveries of common features of different
types of tumor may lead to new therapeutic targets and
drugs for other tumor types also. The discovery of over-
expression of VEGFA and its correlation with poor prog-
nosis in glioblastomas [59] led to trials with the
angiogenesis inhibitor bevacizumab. It is currently being
used to treat recurrent glioblastoma and phase III trials are
being conducted [114, 115].
Rather than single-agent therapy, with which good
responses have been obtained in the treatment of other types
of cancer but which probably will not sufﬁce in the treat-
ment of glioblastoma, combination treatment is necessary.
The clinical response of recurrent glioblastomas to EGFR
Table 5 Frequently identiﬁed microRNA expression alterations in glioblastoma
miRNA Alteration of expression Function of encoded protein Targets Refs.
miR-7 Decreased Increases apoptosis, decreases invasion EGFR [92, 97, 98]
miR-15 Increased Regulator of cell-cycle progression CCNE1 [93]
miR-21 Increased Oncomir, antiapoptosis RECK, PDCD4, PTEN [92, 93, 97]
miR-26 Increased Induces tumor growth, part of oncomir/oncogene
cluster with CDK4 and CENTG1
PTEN and PI3K/Akt pathway [102]
miR-34 Decreased Inhibitor of proliferation, survival, migration, and
invasion
TP53, c-Met, NOTCH1/2 [99]
miR-124 Decreased Inhibitor of proliferation, cell differentiation CDK6, PTBP, SCP1 [97]
miR-125 Increased Inductor of proliferation and inhibitor of apoptosis ERBB2, ERBB3, TP53 [92]
miR-128 Decreased Inhibitor of proliferation BMI1, E2F3a, EGFR [92–94]
miR-137 Decreased Inhibitor of proliferation, cell differentiation CDK6 [97]
miR-155 Increased Regulator of immune response in cells SMAD2 [97]
miR-181 Decreased Reduced colony formation and migration TCL1 [92, 100]
miR-196 Increased Inductor of proliferation, cell differentiation HOXB8, HMGA2, ANXA1 [93]
miR-210 Increased Regulator of proliferation FGFRL-1 [97]
miR-221 Increased Cell proliferation p27Kip1, p57Kip2 [90, 92]
miR-222 Increased Cell proliferation p27Kip1, p57Kip2 [90]
miR-296 Increased Inductor of neovascularization HGS [91]
miR-326 Decreased Reduces cell viability and invasion NOTCH1/2 [101]
miR-451 Increased Inhibitor of migration, inductor of proliferation CAB39 [96]
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123inhibitors was found, in one study, to be associated with
co-expression of EGFRvIII and PTEN [19] or pAkt [116],
but not in combination with TMZ and RT for newly diag-
nosed glioblastomas [117] or in glioblastomas treated with
erlotinib and TMZ [118]. PTEN-deﬁcient glioblastoma
patients could, for example, be treated with a cocktail of
drugs consisting of an EGFR inhibitor and rapamycin [19],
however the results are not yet impressive [119]. The
response to TMZ and RT of patients for whom MGMT
methylation is not observed may be improved by addition of
MGMT-depleting agents, which are currently under inves-
tigation [120]. In this respect, the choice of anti-epileptic
drug may become important as levetiracetam has been
shown to inhibit MGMT expression in a preliminary study
[121]. In addition, MGMT-mediated TMZ resistance may
be overcome by more frequent temozolomide doses in dose-
dense schedules [122]. Thus far, the results are disap-
pointing, and a putative disadvantage of combination
treatment is the potential increase in side effects [123]. This
may, in part, be solved by application of new drug-delivery
techniques. In this ﬁeld, advances have been made with the
application of biodegradable wafers, convection-enhanced
delivery, and strategically-designed liposomes which cir-
cumvent the blood–brain barrier [124, 125]. Recent reviews
have provided up-to date overviews on therapy, and we
refer the reader to those for more details on ongoing and
future therapeutic trials [126].
Synopsis
To summarize, our understanding of the molecular mech-
anisms underlying subgroups of glioblastoma patients has
increased. Moreover, many of the alterations in the afore-
mentioned pathways have been elucidated, and molecular
typing of glioblastomas on the basis of gene expression has
been used to predict prognosis. Furthermore, for the ﬁrst
time it has been shown that the effects of treatment are
distinctly different for different molecular types of glio-
blastoma classiﬁed on this basis [71]. In contrast with
many other forms of cancer, however, subsequent appli-
cation of these results to treatment is lagging behind.
Nevertheless, assessment of the molecular proﬁles of
responding versus non-responding patients can be used to
determine predictive factors and biomarkers, and may lead
to identiﬁcation of new therapeutic targets. Validation of
such new therapeutic approaches will be followed by
stratiﬁed clinical trials based on such molecular subgroups.
Finally, current insights will ultimately lead to more indi-
vidualized therapy for glioblastoma patients. Combination
of current knowledge of molecular alterations in glioblas-
toma with the availability of many drugs with speciﬁc
targets makes investigation of new treatments more
promising than ever before.
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